Evidence map›Paper›PMID 42623842›Full record

ArticleBiochemical and biophysical research communications2026

Molecular mechanisms of protein disulfide isomerase antagonism by punicalagin.

Osamede C Owegie, Rong-Guang Xu, Quinn P Kennedy, Tanvi Penubothu, Ivan Hancco Zirena, Oren Levy, Quoc Quang Luu, Yiliang Chen, Pavel Davizon-Castillo, Yunfeng Chen and 1 more

Abstract read
In one paragraph

Article in Biochemical and biophysical research communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Osamede C OwegieBloodworks Northwest Research Institute, Seattle, WA, 98102, USA.
Rong-Guang XuDepartment of Biochemistry and Molecular Biology and Department of Pathology, University of Texas Medical Branch, Galveston, TX, 77555, USA.
Quinn P KennedyBloodworks Northwest Research Institute, Seattle, WA, 98102, USA.
Tanvi PenubothuBloodworks Northwest Research Institute, Seattle, WA, 98102, USA.
Ivan Hancco ZirenaCentro de Investigación en Medicina de Altura (CIMA), Facultad de Medicina Humana, Universidad de San Martín de Porres, Lima, 15001, Peru.
Oren LevyDepartment of Anesthesia, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA.
Quoc Quang LuuVersiti Blood Research Institute, Milwaukee, WI, 53226, USA.
Yiliang ChenVersiti Blood Research Institute, Milwaukee, WI, 53226, USA; Department of Biochemistry and Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, 53226, USA.
Pavel Davizon-CastilloBen Towne Center for Childhood Cancer Research and the Department of Pediatrics, Seattle Children's Hospital, University of Washington, Seattle, WA, 98102, USA; Division of Hematology and Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, WA, 98102, USA.
Yunfeng ChenDepartment of Biochemistry and Molecular Biology and Department of Pathology, University of Texas Medical Branch, Galveston, TX, 77555, USA.
Moua YangBloodworks Northwest Research Institute, Seattle, WA, 98102, USA; Division of Hematology and Oncology, Department of Medicine, University of Washington School of Medicine, Seattle, WA, 98102, USA. Electronic address: mouayang@uw.edu.

Funding

Inflammation-associated Autophagy DysfunctionR00HL177831 · NHLBI · SEATTLE CHILDREN'S HOSPITAL · PI Pavel Davizon-Castillo · 2025 to 2026
$934k
Oxidative Cysteine Modification by Thiol Isomerases in Sickle Cell DiseaseR00HL164888 · NHLBI · BLOODWORKS · PI Moua Yang · 2024 to 2026
$747k
NHLBI NIH HHS R00 HL164888NHLBI NIH HHS R00 HL177831
6 · The paper itself

Abstract

Punicalagin, an ellagic acid polyphenol from pomegranate, has been proposed as an antagonist of protein disulfide isomerase (PDI) and endoplasmic reticulum resident protein 57 (ERp57)-thiol isomerases that regulate protein folding and extracellular thrombotic signaling. Here, biochemical oxidase and reductase assays on PDI showed that punicalagin inhibits both activities with micromolar potency, thereby extending earlier work that described disulfide reductase inhibition. Using purified domains to determine potential interaction sites indicated that punicalagin antagonizes both the N-terminal a and C-terminal a' domains similarly. Broader profiling of the PDI family demonstrated that punicalagin selectively inhibits the oxidase activity of multiple thiol isomerases while leaving ERp72 unaffected. In parallel, jump-dilution experiments revealed a reversible mechanism of inhibition. Thiol labeling of PDI's catalytic cysteines detected no change in the redox state, supporting a noncovalent, allosteric mechanism. Complementary spectrophotometric and fluorometric assays showed that punicalagin coordinates with zinc to further inhibit PDI, suggesting metal complexation as an additional feature that may shape its interaction with thiol isomerases. Extensive molecular docking and molecular dynamics simulations showed that punicalagin binds stably and preferentially to defined sites on both the N- and C-terminal domains through extensive hydrogen bonding and van der Waals contacts. Finally, artificial intelligence-driven network analysis identified PDI as a high-confidence target of punicalagin and related galloylated polyphenols, alongside additional signaling proteins. Together, these findings provide further mechanistic framework for punicalagin-mediated antagonism of PDI and highlight galloylated polyphenols as promising scaffolds for PDI-targeted therapeutics.

Indexed as

Enzyme InhibitorsHydrolyzable TanninsProtein Disulfide-IsomerasesHumansMolecular Docking SimulationEnzyme InhibitorsHydrolyzable TanninsProtein Disulfide-IsomerasespunicalaginGalloylated polyphenolOxidaseProtein disulfide isomerasePunicalaginReductaseThiol isomerase

Identifiers

PMID42623842
PMCPMC13552022

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.